安罗替尼治疗老年肺癌患者疗效及安全性分析
| 作者: |
1王婧,
1马晓,
1尚昆,
1曹邦伟
1 首都医科大学附属北京友谊医院肿瘤科，北京 100050 |
| 通讯: |
曹邦伟
Email: oncology@ccmu.edu.cn |
| DOI: | 10.3978/j.issn.2095-6959.2022.04.005 |
| 基金: | 北京市临床重点专科基金 (2018-2020)。 |
摘要
目的：探讨安罗替尼对老年肺癌患者疗效及安全性分析。方法：回顾性收集2018年12月1日至2020年5月1日首都医科大学附属北京友谊医院收治的晚期肺癌老年患者73例，均使用安罗替尼治疗，观察患者无进展生存期(progression-free survival，PFS)、总生存期(overall survival，OS)以及药物不良反应情况。结果：安罗替尼的客观有效率(objective response rate，ORR)和疾病控制率(disease control rate，DCR)分别为8.22%、56.16%，PFS为5.2个月，OS为11.2个月。Cox比例风险模型单因素分析显示年龄、病理类型、治疗线数、安罗替尼的使用剂量是影响老年肺癌患者PFS的因素(P<0.05)，性别、病理类型、治疗线数、用药剂量是影响OS的因素，差异均有统计学意义(P<0.05)。多因素分析显示肿瘤分期是影响老年患者中位PFS、OS的因素。安罗替尼的不良反应主要为乏力(27/73，36.90%)、胃肠道反应(24/73，28.70%)、出血(8/73，11%)、高血压(6/73，8.2%)、蛋白尿(5/73，6.8%)等。结论：安罗替尼对老年晚期肺癌患者的疗效好，可改善患者预后，延长生存期，不良反应可控，使用方便，值得临床推广。
关键词：
老年；肺癌；安罗替尼；有效性；安全性
Clinical efficacy and safety analysis of anlotinib in the treatment of elderly patients with lung cancer
CorrespondingAuthor: CAO Bangwei Email: oncology@ccmu.edu.cn
DOI: 10.3978/j.issn.2095-6959.2022.04.005
Foundation: This work was supported by the Key Clinical Specialty Foundation of Beijing, China (2018-2020).
Abstract
Objective: To evaluate the efficacy and safety of anlotinib for elderly patients with lung cancer. Methods: Seventy-three elderly patients with advanced lung cancer admitted to our hospital from December 1, 2018 to May 1, 2020, all of whom were treated with anlotinib, were evaluated retrospectively for progression-free survival (PFS), overall survival (OS), and adverse drug reactions. Results: The objective response rate was 8.22% (6/73) and the disease control rate was 56.16% (41/73). The median PFS and OS were 5.2 months and 11.2 months, respectively. Univariate analysis of a Cox proportional risk model showed that age, pathological type, treatment lines, and anlotinib dosage were factors that affected PFS (P<0.05). Gender, pathological type, treatment lines, and dosage affected OS (P<0.05). Multivariate Cox prognostic analysis showed that clinical stage was an independent predictor of PFS and OS. Adverse reactions were primarily grade 1–2. The most prevalent adverse reactions were fatigue (27/73, 36.90%), gastrointestinal reactions (24/73, 28.70%), hemorrhage (8/73, 11%), hypertension (6/73, 8.2%), and proteinuria (5/73, 6.8%). Conclusion: Anlotinib displayed good short-term efficacy with demonstrable survival benefits, and excellent safety with tolerable adverse reactions.
Keywords：
elder; lung cancer; anlotinib; efficacy; safety